author-photo

Jodi Carey

Janssen Pharmaceutica

5

Papers

185

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (163)
A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (12)